1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > PharmaPoint: Ulcerative Colitis - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Ulcerative Colitis - China Drug Forecast and Market Analysis to 2022

Summary

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Overprescribing of medicines is common in China, as the revenue generated pays for the few quality hospitals that are available. To prevent overprescribing, the Chinese government recently cut the maximum price of about 1,200 commonly used drugs. Also, as a result of China’s progress in reforming its healthcare system under the Five-Year Plan, basic medical coverage had reached more than 90% of the Chinese by the end of 2011.

Scope

- Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the China Ulcerative Colitis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.

Table Of Contents

PharmaPoint: Ulcerative Colitis - China Drug Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 15
3.2 Symptoms 17
3.2.1 Quality of Life 17
4 Disease Management 19
4.1 Diagnosis and Treatment Overview 19
4.1.1 Diagnosis 19
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.1.3 Clinical Practice 24
4.2 China 27
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31
5.3 Product Profiles - Major Brands 32
5.3.1 Remicade (infliximab) 32
5.3.2 Apriso (mesalamine) 38
5.3.3 Asacol HD (mesalamine) 43
5.3.4 Pentasa (mesalamine) 47
5.3.5 Other Drug Classes Used in the Treatment of UC 50
5.4 Biosimilars 51
5.4.1 Introduction 51
5.4.2 Hospira's Inflectra Versus JandJ's Remicade in Key Autoimmune Diseases 52
5.4.3 Biosimilars in the Immunology Community 52
5.4.4 By the Numbers: Biosimilars in Development 53
5.4.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 55
6 Opportunity and Unmet Need 56
6.1 Overview 56
6.2 Unmet Needs 57
6.2.1 Curative Therapy for Severe UC Patients 57
6.2.2 Diagnostic Markers for Disease Severity 57
6.2.3 Personalized Therapy 58
6.2.4 A Replacement for Steroids 58
6.2.5 Novel Oral Drug Formulations 59
6.2.6 Preventative Medicine for Lowering the Associated Colorectal Cancer Risk 60
6.2.7 Improved Management of Infectious Adverse Events 60
6.3 Unmet Needs Gap Analysis 61
6.4 Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools 62
6.5 Predictors of Medically-Refractory Disease 63
7 Pipeline Assessment 64
7.1 Overview 64
7.2 Promising Drugs in Clinical Development 64
8 Market Outlook 66
8.1 China 66
8.1.1 Forecast 66
8.1.2 Key Events 69
8.1.3 Drivers and Barriers 69
9 Appendix 71
9.1 Bibliography 71
9.2 Abbreviations 75
9.3 Methodology 79
9.4 Forecasting Methodology 79
9.4.1 Diagnosed UC Patients 79
9.4.2 Percent Drug-Treated Patients 80
9.4.3 Drugs Included in Each Therapeutic Class 80
9.4.4 Launch and Patent Expiry Dates 80
9.4.5 General Pricing Assumptions 81
9.4.6 Individual Drug Assumptions 81
9.4.7 Generic Erosion 82
9.5 Physicians and Specialists Included in This Study 83
9.6 Primary Research - Prescriber Survey 84
9.7 About the Authors 85
9.7.1 Author 85
9.7.2 Global Head of Healthcare 86
9.8 About GlobalData 87
9.9 Disclaimer 87

1.1 List of Tables

Table 1: Genetic Factors That Confer a Predisposition to UC 15
Table 2: Typical Symptoms of UC 17
Table 3: Truelove and Witts UC Severity Index 21
Table 4: UCDAI 22
Table 5: Treatment Guidelines for UC Used in the 10MM 23
Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013 24
Table 7: UC Management Country Profile - China 29
Table 8: Leading Treatments for UC, 2014 32
Table 9: Product Profile - Remicade 34
Table 10: Remicade SWOT Analysis, 2014 38
Table 11: Product Profile - Apriso 40
Table 12: Apriso SWOT Analysis, 2014 42
Table 13: Product Profile - Asacol HD 44
Table 14: Asacol HD SWOT Analysis, 2014 47
Table 15: Product Profile - Pentasa 48
Table 16: Pentasa SWOT Analysis, 2014 50
Table 17: Summary of Other Immunomodulators for UC, 2013 51
Table 18: Biosimilars Pipeline, 2013 53
Table 19: Overall Unmet Needs - Current Level of Attainment 56
Table 20: Corticosteroid Long-Term Side Effects 59
Table 21: Clinical Unmet Needs in UC - Gap Analysis, 2013 62
Table 22: Prognostic Markers in UC 63
Table 23: UC - Pre-Registration and Phase III Pipeline, 2014 64
Table 24: Comparison of Therapeutic Classes in Development for UC, 2014 65
Table 25: Sales Forecasts ($) for UC in China, 2012-2022 66
Table 26: Key Events Impacting Sales for UC in China, 2012-2022 69
Table 27: UC Market in China - Drivers and Barriers, 2012-2022 69
Table 28: Key launches for Ulcerative Colitis, 2012-2022 80
Table 29: Key Patent Expiries 81
Table 30: Annual Cost of Therapy for 5-ASAs ($) 82
Table 31: Physicians Surveyed, By Country 84

1.2 List of Figures

Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC 16
Figure 2: UC Disease Management Flowchart 27
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012-2022 65
Figure 4: Sales for UC in China by Drug Class, 2012-2022 68

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.